NEW YORK (GenomeWeb News) – Teva Pharmaceuticals will be the exclusive distributor of MDxHealth's tests for prostate cancer and glioblastoma in Israel under a deal announced today.

The three-year agreement provides Teva the exclusive rights to distribute MDxHealth's ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma in Israel. MDxHealth will analyze samples in its CLIA-registered laboratory in Irvine, Calif., and Teva will reimburse MDxHealth for all testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.